REPLIGEN CORP (NASDAQ: RGEN) will see director Karen A. Dawes retire from its board effective September 30, 2026, after more than two decades of service. Dawes linked the timing to the completion of a successful CEO transition.
Scholar Rock Holding Corp (NASDAQ: SRRK) said ISEMBYLD has received FDA approval for spinal muscular atrophy treatment in adults and children receiving an SMN2-targeted therapy. The approval carries safety-related obligations that management had incorrectly described during the company’s September 14, 2026, investor call.
TAKEDA PHARMACEUTICAL CO LTD (NYSE: TAK) Chief Transformation Officer Duprey Lauren Rusckowski sold 34,535 shares at $18.54 per share. The transaction left Rusckowski with 191,522 shares.
The offering prices are $22.0300 per share and $22.0290 per pre-funded warrant, producing a total offering price of $400,001,285.34. Tyra Biosciences (NASDAQ: TYRA) is the issuer and delivery was expected on or about September 15, 2026.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Chief Accounting Officer Theodore Alan Huizenga sold 1,283 shares at $13.57 per share. The transaction was completed on 15 September 2026.
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) awarded 171,774 derivative securities across two transactions. Dornan David, the company’s chief scientific officer, received the awards.
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) awarded Bryan Ball 183,266 derivative securities across two transactions. The transactions listed a per-share award price of $0.
Wilson Martin sold 75,364 Rocket Pharmaceuticals shares at $3.40 per share on 11 September 2026, in a transaction representing about 11.2% of his prior holding.
Jones Keith Anthony bought 10,000 shares of Humacyte, Inc. (NASDAQ: HUMA) at $0.56 per share. The purchase was reported on 14 September 2026.
Imunon, Inc. (NASDAQ: IMNN) awarded 4,211 shares to Chief Medical Officer Faller Douglas Vincent. The shares were issued at $1.47 per share. The filing identifies this as an award to the company’s medical officer.